ImmuneOnco Reveals Global Cancer Drug Strategy

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced an update on its global strategy for IMM2510, a bispecific antibody for treating non-small cell lung cancer and triple-negative breast cancer. The company is advancing IMM2510’s development with planned Phase 1b/2 trials in China and a partnership with Instil Bio, Inc. to commence trials in the United States. The antibody, which targets multiple solid tumor cancers, is unique for its VEGF trap and enhanced ability to kill PD-L1-positive tumor cells.

For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.